enGene Secures $125M Debt Facility, Extends Cash Runway to 2028, Eyes 2H 2026 BLA Filing
summarizeSummary
enGene Holdings Inc. announced a significant strengthening of its financial position and a clear path forward for its lead drug candidate, detalimogene. The company expanded its existing debt facility with Hercules Capital (HTGC) by $125 million, providing substantial non-dilutive capital. This, combined with current cash and marketable securities of $312.5 million, is expected to extend enGene's cash runway into the second half of 2028. Furthermore, enGene provided an update on its LEGEND pivotal cohort, with a further update planned for a spring 2026 medical conference and 12-month complete response data expected in 2H 2026. Critically, the company plans to submit a Biologics License Application (BLA) for detalimogene in the second half of 2026, targeting a potential launch in 2027. This news significantly de-risks the company's operations by securing funding for key development milestones and provides a concrete timeline for regulatory submission, which is highly positive for a clinical-stage biotech.
At the time of this announcement, ENGN was trading at $8.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $581.5M. The 52-week trading range was $2.65 to $12.25. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.